IMPORTANT LEGAL NOTICE - The information on this site is subject to adisclaimerand acopyright notice
Contact   |   Search  
Graphical element Graphical element Graphical element Graphical element Graphical element Graphical element Graphical element Graphical element Graphical element
Cell factory - Back to the homepage Graphic element Graphical element
Foreword Graphic element Graphical element
Table of contents Graphical element
Index by Index by Area Index by Partners Index by Keywords Graphic element Graphical element
Volume 2 Graphical element

[ Area 3.1 ]
Improving the diagnostic and therapeutic arsenal for health care [ Introduction ]
[ Area 3.2 ]
Improving environmental sustainability [ Introduction ]
[ Area 3.3 ]
New biological and biotechnological products and processes for
agro-industry, agri-food and high value added chemicals
[ Introduction ]
Graphical element
Area 3.1
Graphical element
QLK3-2001-00090 Stable extracellular matrices as novel biotherapeutics for biomimetic induction of hard tissue growth (MATRIX)
QLK3-2001-00093 Biochemical and functional characterisation of antigen-presenting cell-derived exosomes: The design of a cell-free cancer vaccine (EXOSOME)
QLK3-2001-00225 Innovative therapeutics for the prototype autoimmune disease, myasthenia gravis (Immunotherapeutics)
QLK3-2001-00244 Novel in vitro testing platforms based on intra- and extracellular sensing (CellSens)
QLK3-2001-00277 Development of novel anti-bacterials and anti-infectives that target programmed bacterial cell death (BAS anti-microbials)
QLK3-2001-00283 Integrated in vitro and in vivo testing of drugs in prion diseases: screening, development and mechanisms of novel therapeutics (STOPTSEs)
QLK3-2001-00305 Deoxyuridine triphosphate nucleotidohydrolase as drug target for the control of protozoal and bacterial infections (dUTPase)
QLK3-2001-00401 Prevalidation of novel alternative pharma-/toxicological screening based on yeast expression technology (MULTIPLEX)
QLK3-2001-00407 Organotypic brain slice cultures as an alternative to in vivo experimentation in the study of brain repair mechanisms (ORCA)
QLK3-2001-00422 Targeting heme-oxygenase-1 or downstream processes: A new therapeutic approach for treatment of inflammation (HO-1)
QLK3-2001-00427 Gene therapy of hematopoietic stem cells for inherited diseases (INHERINET)
QLK3-2001-00498 Therapeutic molecules for modulation of ligand-receptor mediated apoptosis (Triskel)
QLK3-2001-00506 Research, selection and mechanism of action of potential therapeutic agents against Flaviviridae (Hepatitis C virus, Dengue virus, West Nile virus) (Flavitherapeutics)
QLK3-2001-01104 Novel therapeutic tools and strategies to fight polycystic kidney disease (GTPKD)
QLK3-2001-01982 Novel gene chip technology for simplified detection of molecularly heterogeneous genetic diseases: Detection of cystic fibrosis as a model (CF-CHIP)
QLK3-2001-02166 A Fusion Gene for the Treatment of Cancer (Scavidin)
QLK3-2002-01772 Blood grouping and genotyping: Improving patient safety and blood transfusion compatibility (BloodGen)
QLK3-2002-01775 Demonstration of the clinical utility of holoTC as an early marker of vitamin B12 deficiency (HoloTC)
QLK3-2002-01777 Generation of bioengineered pancreatic islet micro-organs for insulin replacement therapy in diabetes mellitus (Pseudoislet)
QLK3-2002-01918 Evaluation of the facilitation of umbilical cord blood transplant engraftment using ex vivo haematopoietic progenitors/stem cell expansion (EUROCORD III)
QLK3-2002-01936 Predicting outcome and developing new therapeutic strategies for haematological stem cell transplant recipients using in vitro techniques (TRANSEUROPE)
QLK3-2002-01949 Integrated strategy for efficient therapeutic retrovirus production based on modular cell lines (InsertAGene)
QLK3-2002-01955 Therapeutic strategies using VEGF substitutes and gene therapies to maintain the integrity of the arterial wall (VEGF Strategies)
QLK3-2002-01956 Interplay among mitochondria and p53 family proteins during apoptosis induced by DNA damage: A new strategy for cancer therapy (IMPALED)
QLK3-2002-01980 Development of an immunotherapy for breast cancer based on dendritic cells by developing and comparing different types of tumour-specific immunogens (Cancer Immutherapy)
QLK3-2002-01997 Novel GENE DRUG strategy based on hybridisation of functional entities to plasmids (EURO GENE DRUG)
QLK3-2002-02003 European standard operating procedures for electrochemotherapy and electrogenetherapy (ESOPE)
QLK3-2002-02010 A prime boost strategy for immunotherapy of breast and ovarian cancer (Prime Boost Ca Vaccine)
QLK3-2002-02017 Clearance of apoptotic cells: Discovery of autoantigens and therapy for autoimmune diseases (APOCLEAR)
QLK3-2002-02026 Allergen-derived DNA vaccines: Mechanisms involved in mouse and human models (ALLDNAVAC)
QLK3-2002-02029 Synthesis and mechanism of action of novel classes of retinoids and rexinoids with antineoplastic activities
QLK3-2002-02031 Neuropeptides for lung treatment of rare lung diseases, primary and secondary pulmonary hypertension (Neuropeotide Lung Therapy)
QLK3-2002-02039 Engineered mesenchymal stem cells combined with gene therapy for osteoarticular diseases (STEMGENOS)
QLK3-2002-02049 Heparanase inhibitors in antiangiogenic and antimetastatic cancer therapy (HEPARANASE)
QLK3-2002-02052 Semliki Forest virus based therapeutic systems (SFVECTORS)
QLK3-2002-02059 Targeting signals essential for angiogenesis: Gene therapy to prevent new vessel formation and to induce apoptosis and necrosis of tumour vasculature (anti-tumour angiogenesis)
QLK3-2002-02062 The alternative splicing database A novel tool to diagnose human disease (ASD)
QLK3-2002-02114 European network to develop new therapeutic strategies for Parkinson's Disease using lentiviral vector technology ((N)EUROPARK)
QLK3-2002-02119 Development and application of chromosome-based gene transfer vectors for cell therapy (Chromosome therapy)
QLK3-2002-02127 Demonstrating the applicability of novel indices of immunological tolerance to clinical practice using immunosuppression-free transplant recipients (Indices of tolerance)
QLK3-2002-02136 Profiling metalloproteinase inhibition for tumour therapy
QLK3-2002-02149 Anchored cAMP signaling implications for treatment of human disease (cAMP signalling)
Graphical element
Area 3.2
QLK3-2001-00101 Testing integrated GM-Rhizoremediation systems for soil bioremediation (GM-Rhizoremediation)
QLK3-2001-00345 Molecular and engineering approach to anaerobic degradation of recalcitrant xenobiotic compounds: In situ removal of nitro- and aminoaromatic chemicals (MADOX)
QLK3-2001-00403 Whole-cell Baeyer-Villiger monooxygenase biocatalysts: Methodologies for exploitation (BIOMEX)
QLK3-2001-00429 Development of systems to improve phytoremediation of metal contaminated soils through improved phytoaccumulation (PHYTAC)
QLK3-2002-01923 Biosensors for in situ evaluation of bioavailability of pollutants based on transcriptional regulators la carte (BIOCARTE)
QLK3-2002-01933 Eco-genomic survey of microbial diversity for lindane degradation: Formulation of catalysts for site intervention (LINDANE)
QLK3-2002-01938 Phototrophic biofilms and their potential applications: Towards the development of a unifying concept (PHOBIA)
QLK3-2002-01939 Micro-arrays for the detection of the abundance and distribution of pathogenic protozoa, flagellated algae and diatoms (MICROPAD)
QLK3-2002-01969 Protecting the benefits of Bt-toxins from insect resistance development by monitoring and management (ProBenBt)
QLK3-2002-01973 Developing single nucleotide polymorphism (SNP) markers for adaptive variation in forest trees (TREESNIPS)
QLK3-2002-02063 Development and risk assessment of a field-based portable biosensor using genetically-modified bioluminescent bacteria (BIOGEM)
QLK3-2002-02068 Soil metagenomics to identify novel mechanisms of antagonism and antifungal activity for the improved control of phytopathogens (METACONTROL)
QLK3-2002-02075 Novel surfaces for switchable nucleic acids adsorption/desorption for analytical assays (DNA Switch)
QLK3-2002-02098 Pararetroviruses: Disease, integration and genomes (PARADIGM)
QLK3-2002-02140 Environmental impact assessment of transgenic grapevines and plums on the diversity and dynamics of virus populations (TRANSVIR)
QLK3-2002-02141 Development of a capacitance based immunodetection analyser for the assay of genetically modified organisms in foods (IMAGEMO)
QLK3-2002-02151 Ciliates as monitors for environmental safety of GMO (CIMES)
Graphical element
Area 3.3
QLK3-2001-00149 Combinatorial engineering of glycoside hydrolases from the alpha-amylase superfamily (CEGLYC)
QLK3-2001-00278 Sensing and controlling single molecules by novel electrical, mechanical and optical methods with applications to nanobiotechnology (NANOCELL)
QLK3-2001-00435 Solvent tolerant bacteria allowing a broader performance of biotransformations of organic compounds in two phases (BARTOLO)
QLK3-2001-00448 Development of highly specific enzymes for genome manipulation (EnGeM)
QLK3-2001-00519 Directed evolution of enantioselective biocatalysts (EvoCatal)
QLK3-2001-00533 Engineering yeast for efficient expression of heterologous membrane transporters (EFFEXPORT)
QLK3-2002-01930 Investigation of biochemical and genetical diversity of terpenoid biosynthesis for the production of high value-added compounds (INTESY)
QLK3-2002-01940 Eukaryotic polyketides in surrogate hosts (EUKETIDES)
QLK3-2002-01945 Improving arable production systems by expressing marine algal rubisco in crop plants (MARISCO)
QLK3-2002-01967 Silicon biotechnology: Biofabrication of nanostructured silica and use of enzymes involved in metabolism of biogenic silica in industry and medicine (SILIBIOTEC)
QLK3-2002-01972 Multigenome access technology for industrial catalysts (MGAtech)
QLK3-2002-02032 Functional genomics and proteomics of Trichoderma antagonist strains for industry and agriculture (TRICHOEST)
QLK3-2002-02035 Compendium of Arabidopsis gene expression (CAGE)
QLK3-2002-02038 Demonstration of increased yield and productivity in selected commercial organisms by strategic transformation of key genes from Aspergillus niger (ANTICO)
QLK3-2002-02056 Gene mining of metagenomes for novel enzymes and therapeutics (Gemini)
QLK3-2002-02071 DNA replication and biotechnological applications (REPBIOTECH)
QLK3-2002-02086 Exploiting the secretion machinery of Pseudomonas for the nanotechnological production of pharmaceuticals (NANOFOLDEX)
QLK3-2002-02097 Developing a genomic toolbox for exploring and exploiting bacterial biodiversity (BACDIVERS)
QLK3-2002-02132 Microalgae as cell factories for chemical and biochemical products (ALGINET)
Graphical element